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P-glycoprotein, encoded by the mdrl gene causes classical multidrug resistance (MDR). This is characterized by resistance of tumour cells to a wide variety of anti-cancer drugs. P-glycoprotein causes cellular efflux of such drugs, a process that can be reversed by so-called resistance modifiers, e.g. verapamil, cyclosporins and quinidine (Fojo, 1991) .
A large proportion of human tumour types have been investigated for mdrl gene expression, which was initially described in drug-selected cell lines. Acute leukaemias have been extensively studied, and in several studies mdrl gene expression in acute myelocytic leukaemia (AML) was an adverse prognostic factor (Campos et al, 1992; Te Boekhorst et al, 1995; Leith et al, 1997) . However, there are also studies that could not confirm this finding (Ino et al, 1994) . Mdrl gene expression has also been detected in lymphomas and in solid tumours, such as breast cancer, ovarian cancer and osteosarcomas, but its relationship to treatment results is less clear (Goldstein et al, 1992; Arao et al, 1994; Yuen and Sikic, 1994; Lee et al, 1996; Linn et al, 1996) . In small clinical studies of AML and multiple myeloma, promising results have been reported when resistance modifiers have been added to chemotherapy, and trials are under way to investigate whether this can improve treatment results (Sonneveld et al, 1992; List et al, 1993) . Clinical studies in solid tumours are, so far, mostly phase I or contain few patients and are therefore not conclusive (Raderer and Scheithauer, 1993) .
More recently, it was shown that multidrug resistance can also be conferred by the transport protein multidrug resistanceassociated protein (mrp) (Cole et al, 1992) . Its clinical relevance is still unclear but there have been studies that have demonstrated an increase of mrp expression in relapsed AML (Hart et al, 1994; Schneider et al, 1995) .
The radiopharmaceutical 99Tcm-hexaxis-2-methoxyisobutyl isonitrile (99Tcm-MIBI, 99Tcm-Sestamibi, Cardiolite), originally developed for myocardial scintigraphy, has been shown to be a substrate for P-glycoprotein (Piwnica-Worms et al, 1993) . In cell lines with different levels of P-glycoprotein expression, the accumulation of 99Tcm-MIBI and the effect of resistance modifiers were proportional to the level of P-glycoprotein expression (Ballinger et al, 1995; Piwnica-Worms et al, 1995) .
The level of mdrl gene expression in tumours is, however, lower than in drug-selected cell lines. Using a quantitative RNAase protection assay, we found the median level of mdrl mRNA in positive cell samples from patients with AML to be 0.7 mdrl mRNA transcripts per cell (Gruber et al, 1992) . In two vincristine-selected K562 cell lines, the levels were approximately 100 and 200 transcripts per cell.
The aim of the present study was to investigate whether 99Tcm-MIBI can be used to detect the rather low mdrl gene expression found in human tumours. We therefore compared the accumulation of 99Tcm-MIBI and the effect of cyclosporin A (CyA) in leukaemic cell samples with and without mdrl gene expression. We also investigated whether the effect of CyA on cellular 99Tcm-MIBI accumulation was similar to the effect on daunorubicin (Dnr).
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MATERIALS AND METHODS Cell lines
The human leukaemic cell line K562, two vincristine-selected sublines grown in 30 and 150 nM vincristine (K562/Vcr30, K562/Vcrl50) and a mitoxantrone-resistant subline grown in mitoxantrone 100 ng ml' (K562/Mxn) were used. K562/Vcr3O and K562fVcrl50 expressed approximately 100 and 200 mdrl mRNA transcripts per cell, respectively, as determined by a quantitative RNAase protection assay (Gruber et al, 1992 Leukaemic cells Peripheral leukaemic cells from ten patients with AML were used. Cells isolated on Lymphoprep (Nycomed, Pharma, AS, Norway) were frozen in a programmed freezer and kept in liquid nitrogen. The patients, peripheral white blood cell counts ranged from 32 to 363 x 109 1-1 (median 80 x 109 1-'), and the percentage of leukaemic cells was between 70% and 100% (median 90%). The viability of the cells after thawing was controlled with trypan blue exclusion and was 70% and 73% in two samples; in the remaining, the viability was over 85%. The samples were chosen according to their mdrl mRNA expression, which was determined earlier with a quantitative RNAase protection assay (Gruber et al, 1992) . Cells from five of the patients had no detectable mdrl mRNA levels, and cells from five patients had mdrl mRNA levels ranging from 1.0 to 3.8 mdrl mRNA transcripts per cell. That the function of P-glycoprotein in thawed leukaemic cells is comparable to that in fresh cells has been demonstrated by Broxterman and co-workers (Broxterman et al, 1996) .
The mdrl mRNA expression and also the mrp mRNA expression was reanalysed with a quantitative reverse transcription polymerase chain reaction (RT-PCR) method with some modifications (Xu et al, 1996) . By this method, the median mdrl mRNA expression in the samples found to be negative with the RNAase protection assay was 0.04 transcripts per cell (range 0.01-0.28) and in the positive samples 8.8 transcripts per cell (range 1.4-15.8). Mrp expression was positive in all samples, median 2.3 transcripts per cell (range 0.5-4.0) in mdrl mRNA-negative samples and 3.1 transcripts per cell (range 1.5-4.2) in the mdrl mRNA-positive samples, P = 0.2.
Incubation of cells with 99Tcm-MIBI and daunorubicin
From cell lines and patients, 0.5 and 1.0 x 106 cells, respectively, were incubated in triplicates for 1 h at 37°C in 1 ml of RPMI 1640 medium (Gibco, Glasgow, UK), supplemented with 10% newborn calf serum and 2 mM L-glutamine, with 3-5 x 106 c.p.m. 99Tcm-MIBI (Du Pont, Stevenage, UK). The incubations were performed with and without CyA 3 gM (Sandoz, Basle, Switzerland) . Cell line cells were also incubated with higher concentrations of CyA (10 and 20 gM). The incubations were stopped by centrifugation at 4°C for 5 min. After two washes with ice-cooled phosphatebuffered saline (PBS), the activity of the cells was assessed with a well-type gamma-counter (1282 Compugamma, LKB-Wallac, Bromma, Sweden). Correction was made for decay of 99Tcm during the measuring time to obtain a maximal statistical uncertainty of 3%, indicated as one standard deviation. Approximately 2.0 x 106 of the patient and cell line cells were incubated in duplicates for 1.5 h at 37°C in 2 ml of medium containing 1 gM Dnr with and without CyA 3 gM. Dnr incubations were stopped by addition of 5 ml of ice-cooled PBS to the tubes and centrifugation at 4°C for 5 min. After two washing steps with PBS, the cellular Dnr content was analysed with high-performance liquid chromatography (Baurin et al, 1978) .
Statistical analyses
The differences in 99Tcm-MIBI and Dnr accumulation, and effects of CyA in mdrl-negative and -positive patient samples were analysed using the Mann-Whitney test. Correlations between the effect of CyA on cellular 99Tcm-MIBI and Dnr accumulation were analysed with linear regression analysis. A P-value of < 0.05 was set as significant. (Figure 1 ). CyA 3 ,uM increased 99Tcm-MIBI accumulation in K562/Vcrl5O with 662% from 1.9% to 14.5% of that in K562 without CyA, and in K562/Vcr3O with 1342% from 2.7% to 37.3% of that in K562.
CyA, 10 and 20 gM, further increased the 99Tcm-MIBI accumulation in the resistant cell lines but not reaching the same level as in K562. In the maternal line and in K562/Mxn, the increase caused by CyA was the same at all three concentrations, approximately 40% and 50% respectively (Figure 1) . 
Accumulation of 99Tcm-MIBI and daunorubicin in patient leukaemic cells
The median accumulation of 99Tcm-MIBI in the five cell samples from patients with undetectable mdrl mRNA expression was 0.89% of the input (range 0.73-1.39), compared with the five samples positive for mdrl mRNA, which accumulated 0.34% (range 0.15-0.73; P = 0.012) (Figure 2A ).
The median increase in 99Tcm-MIBI accumulation caused by (Figure 3) .
In nine of the samples, there was a strong correlation between the increase caused by CyA 3 JM on 99Tcm-MIBI and Dnr accumulation (r = 0.87, P = 0.0023). Because of a large effect on Dnr accumulation (74% increase) in one mdrl-negative sample, the correlation was not statistically significant for all ten samples, P = 0.19 (Figure 4 ).
DISCUSSION
The results of this study show that the difference in cellular 9Tcm-MIBI accumulation between K562 and the mdrl gene-expressing K562/Vcrl5O was much larger than the difference in Dnr accumulation. 99Tcm-MIBI accumulation in KS62Ncrl50 was only 1.9% of that in K562 compared with Dnr accumulation, which was 29%.
CyA 3 gM restored Dnr accumulation in K562Ncrl5O to the same British Journal of Cancer (1998) 77(11), 1732-1736 1 99Tcm-MIBI for detection of P-glycoprotein function 1735 level as that in the maternal line, while 99Tcm-MIBI by the same CyA concentration was increased to only 14.5% of that in K562. Consistent with the results of Piwnica-Worms and co-workers (1993), the increase in 99Tcm-MIBI accumulation caused by CyA 3 FtM was larger in K562Ncr3O, with a lower degree of resistance than in K562/Vcrl50. The results confirm the very high affinity of 99Tcm-MIBI to P-glycoprotein and its high sensitivity to detect P-glycoprotein expression.
The high affinity of 99Tcm-MIBI to P-glycoprotein is confirmed by the fact that the cellular accumulation of 99Tcm-MIBI was much lower in the mdrl gene-expressing human leukaemic cell samples than in the samples with undetectable mdrl expression. In contrast, for Dnr, there was only a non-significant trend towards lower accumulation in mdrl-positive than in mdrl-negative samples. In parallel, the increase in cellular accumulation caused by CyA in mdrl-positive samples was much larger for 99Tcm-MIBI than for Dnr (median 242% vs 40%) . Although the increase caused by CyA 3 gM was much larger for 99Tc--MIBI than for Dnr, in nine of the samples there was a correlation between the effect on the two, which is a prerequisite for the use of 99Tcm-MIBI in vivo for functional monitoring of P-glycoprotein activity. In one mdrl mRNA-negative sample, CyA 3 gM increased the cellular Dnr accumulation by 74%, while the increase for 99Tc--MIBI was only 18%. One explanation for this discrepancy could be the existence of other transport proteins for which 99Tcm-MIBI is not a substrate. Dnr is also transported by mrp. Whether 99Tcm-MIBI is a substrate for mrp is unknown. However, all our samples were positive for mrp expression, in the case in question four transcripts per cell. Moreover, CyA was shown to be a rather poor modifier of reduced Dnr accumulation in mrp-positive cells (Barrand et al, 1993) . Consequently, it seems likely that the increase in Dnr accumulation caused by CyA in this sample is a result of mechanisms other than mrp expression.
The potential use of 99Tcm-MIBI as a marker for P-glycoprotein and the effect of resistance modifiers in vivo has recently been demonstrated by Luker and co-workers (1997) . 99Tcm-MIBI scintigraphy with and without the resistance modifier PSC-833, a cyclosporin D analogue, was performed on three patients. With administration of the modifier, 99Tcm-MIBI was selectively retained in the liver and kidneys, two organs with high expression of P-glycoprotein. In a study of patients with untreated breast cancer, the efflux rate of 99Tcm-MIBI was faster from tumours with high than from those with low P-glycoprotein expression (Vecchio et al, 1997) .
The results of 99Tcm-MIBI scintigraphy before chemotherapy have also been related to treatment response in a few patients with breast cancer (Moretti et al, 1996) and malignant lymphomas. Kapucu and co-workers (1997) found, in a study of 24 children with untreated malignant lymphomas, that children with positive scans responded better to chemotherapy than those with negative scans.
The results of trials in solid tumours when resistance modifiers were added to chemotherapy are often difficult to interpret. Only some patients seem to respond (Raderer and Scheithauer, 1993 ). An assay that can monitor P-glycoprotein function and the effect of resistance modifiers would be a tool to select, for example, patients with malignant lymphoma who may benefit from addition of resistance modifiers to chemotherapy (Miller et al, 1991; Sarris et al, 1996) .
In summary, our results show that 99Tcm-MIBI is very sensitive in detecting mdrl gene expression at the low, but probably clinically relevant, levels that are present in human tumour cells.
Secondly, the effect of CyA 3 gM on cellular 99Tcm-MIBI accumulation seems to reflect the effect on cytostatic drugs (at least daunorubicin).
99Tcm-MIBI is a well-established radiopharmaceutical for myocardial scintigraphy used routinely world-wide since about 1990. As is the case for most radiopharmnaceuticals, the amount of chemical substrate administered is very low, and adverse reactions are rare. The effective dose equivalent of a typical administered activity of 500 MBq is 7 mSv compared with approximately 5 mSv for an abdominal computerized tomography examination.
Consequently, 99Tcm-MIBI scintigraphy has the potential of being used to monitor the effect of resistance modifiers on the accumulation and retention of cytostatic drugs in human tumours, e.g. lymphomas, in vivo. The use of 99Tcm-MIBI scintigraphy in clinical trials in which resistance modifiers are added to chemotherapy will answer whether it can be used to predict the efficacy of such treatment.
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